Sildenafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C22H30N6O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3M7OB98Y7H, chemically known as 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine but generally known as sildenafil, which bears US NIH Compound Identifier 5212. European Medicines Agency schedules Sildenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10517MIG. The term SILDENAFIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules sildenafil in its Anatomical Therapeutic Chemical (ATC) Classification. SILDENAFIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sildenafil under HS 29350090 and SITC 51580. As of Q4 2014, SILDENAFIL remains the US FDA Preferred Term for this commodity. Sildenafil bears US NLM identifiers UMLS ID C0529793 and NCI Concept Code C61940. SMILES: S(=O)(=O)(N1CCN(CC1)C)C1CC(C2[NH]C3C(NN(C3C(=O)N2)C)CCC)C(OCC)CC1.